Key result
LVH prevalence in overweight and obese hypertensives is higher when LVM is normalized to height^2.7 compared with BSA, whereas the opposite occurs in normal weight/lean hypertensives (p<0.05).
Why the study?
Does the method of left ventricular mass indexation (height^2.7 vs body surface area) affect the detected prevalence of left ventricular hypertrophy across different BMI categories in essential hypertensives?
Cross-Sectional (n=4,468)
Does the method of left ventricular mass indexation (height^2.7 vs body surface area) affect the detected prevalence of left ventricular hypertrophy across different BMI categories in essential hypertensives?
p-value: p=<0.05
The choice of left ventricular mass indexation method significantly alters the detected prevalence of LVH depending on patient BMI, with BSA indexation underestimating LVH in obesity and height^2.7 indexation underestimating it in lean individuals.
LVM indexation method alters LVH prevalence by BMI category; leaves open optimal normalization for risk stratification in hypertension.
BACKGROUND AND AIM: Weight and height are two major determinants of left ventricular mass (LVM); the anthropometric parameter to which LVM should be normalized remains, however, debated. In a population of hypertensives, we compared the prevalence of left ventricular hypertrophy (LVH) defined by two indexation criteria of LVM in different subgroups of body mass index (BMI). METHODS: A total of 4468 essential hypertensives included in the Evaluation of Target Organ Damage in Hypertension (ETODH), were divided in four groups according to BMI thresholds: lean (BMI<20 kg/m(2), 4.5%), normal (20-24.9 kg/m(2), 36.5%), overweight (25-29.9 kg/m(2), 41.9%) and obese (≥ 30 kg/m(2), 17.1%). All patients underwent quantitative echocardiography; LVH was defined by two criteria of LVM indexation: (A) ≥ 116 g/m(2) in men and ≥ 96 g/m(2) in women; (B) ≥ 49 g/m(2.7) in men and ≥ 45 g/m(2.7) in women. RESULTS: Overall, 44.9% of the patients were found to have LVH by criterion A, 48.2% by criterion B and 37.0% by both criteria. Prevalence rates of LVH in the four BMI groups were 34.3%, 40.5%, 47.3%, 53.9% by criterion A, 19.8%, 37.0%, 53.6%, 69.7% by criterion B, and 14.2%, 30.9%, 41.5%, 47.8% by both criteria, respectively (p at least <0.05 for all). CONCLUSIONS: Our findings show that LVH prevalence in both overweight and obese hypertensives is higher when LVM is normalized to height(2.7) compared with body surface area (BSA), whereas the opposite trend occurs in normal weight/lean hypertensives. Thus, the risk related to LVH is underestimated when the LVH/height(2.7) criterion is applied to lean/normal weight individuals and the LVH/BSA criterion in overweight/obese individuals.
No takes yet. Share an insight, caveat, or question.
Cuspidi et al. (2010) conducted a cross-sectional in essential hypertension (n=4,468). LVM indexation to height^2.7 vs. LVM indexation to body surface area (BSA) was evaluated on Prevalence of left ventricular hypertrophy (LVH) (p=<0.05). LVH prevalence in overweight and obese hypertensives is higher when LVM is normalized to height^2.7 compared with BSA, whereas the opposite occurs in normal weight/lean hypertensives (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: